• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

去纤苷活性的综合观点。

An integrated view of the activities of defibrotide.

作者信息

Pescador R, Porta R, Ferro L

机构信息

Crinos Biological Research Laboratories, Villa Guardia (CO), Italy.

出版信息

Semin Thromb Hemost. 1996;22 Suppl 1:71-5.

PMID:8807733
Abstract

Defibrotide is a polydeoxyribonucleotide sodium salt extracted from mammalian organs. Its mean molecular weight is 15,000-30,000 daltons. Defibrotide contains aptamers, i.e., single-stranded polynucleotides with a well-defined base sequence and composition (5'-GGTTGG-ATT-GGTTGG-3' and 5'-GGTTGG-ATC-GGTTGG-3') that bind thrombin. For the time being, these aptamers are the only ones that have been identified in defibrotide, but there may also be other aptamers that bind proteins other than thrombin. Defibrotide has no anticoagulant activity, but in some other aspects it probably parallels heparin. Heparin is a sulfated polysaccharide sodium salt with a mean molecular weight ranging from 5,000 to 40,000 daltons extracted from mammalian organs. It contains disaccharide sequences of well-defined structure and frequency. Heparin binds an array of proteins, enzymes, and growth factors and shows inhibitory or stimulatory or protective activity. Defibrotide has a spectrum of interesting pharmacological properties that make this drug very useful for the treatment of arterial and venous thrombotic diseases. In fact, defibrotide has profibrinolytic, antithrombotic-thrombolytic, anti-ischemic, and antiatherosclerotic activity and protective activity in shock. What have all the above activities to do with a single drug? The explanation is that atherosclerosis, myocardial, renal, and liver ischemia, hemorrhagic and septic shock, and shock induced by occlusion of splanchnic artery and thrombosis are different facets of the same entity: the polyhedric inflammatory process.

摘要

去纤苷是一种从哺乳动物器官中提取的多脱氧核糖核苷酸钠盐。其平均分子量为15,000 - 30,000道尔顿。去纤苷含有适体,即具有明确碱基序列和组成的单链多核苷酸(5'-GGTTGG-ATT-GGTTGG-3'和5'-GGTTGG-ATC-GGTTGG-3'),可结合凝血酶。目前,这些适体是在去纤苷中已鉴定出的仅有的适体,但可能还存在其他能结合除凝血酶以外蛋白质的适体。去纤苷没有抗凝活性,但在其他一些方面可能与肝素相似。肝素是一种从哺乳动物器官中提取的平均分子量为5,000至40,000道尔顿的硫酸化多糖钠盐。它含有结构和频率明确的二糖序列。肝素能结合一系列蛋白质、酶和生长因子,并表现出抑制、刺激或保护活性。去纤苷具有一系列有趣的药理特性,使这种药物对治疗动静脉血栓性疾病非常有用。事实上,去纤苷具有促纤溶、抗血栓 - 溶栓、抗缺血和抗动脉粥样硬化活性以及在休克中的保护活性。上述所有活性与单一药物有什么关系呢?解释是动脉粥样硬化、心肌、肾脏和肝脏缺血、出血性和脓毒性休克以及由内脏动脉闭塞和血栓形成引起的休克是同一实体的不同方面:多面性炎症过程。

相似文献

1
An integrated view of the activities of defibrotide.去纤苷活性的综合观点。
Semin Thromb Hemost. 1996;22 Suppl 1:71-5.
2
Defibrotide: properties and clinical use of an old/new drug.地夫可特:一种老药/新药的特性和临床应用。
Vascul Pharmacol. 2013 Jul-Aug;59(1-2):1-10. doi: 10.1016/j.vph.2013.05.001. Epub 2013 May 14.
3
Fibrinolytic effects of defibrotide in atherosclerotic patients.去纤苷对动脉粥样硬化患者的纤溶作用。
Semin Thromb Hemost. 1991;17 Suppl 1:101-5.
4
Absorption through the peritoneum of the macromolecular profibrinolytic drug defibrotide in the rabbit.兔体内大分子纤溶药物去纤苷通过腹膜的吸收情况。
Semin Thromb Hemost. 1991 Oct;17(4):404-6. doi: 10.1055/s-2007-1002644.
5
Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders.去纤苷。对其药效学和药代动力学特性以及在血管疾病中的治疗用途的综述。
Drugs. 1993 Feb;45(2):259-94. doi: 10.2165/00003495-199345020-00007.
6
Clinical pharmacology and mode of action of a new antithrombotic compound: Defibrotide.一种新型抗血栓化合物去纤苷的临床药理学及作用机制
Folia Haematol Int Mag Klin Morphol Blutforsch. 1988;115(1-2):177-80.
7
Defibrotide as a possible anti-ischemic drug.去纤苷作为一种潜在的抗缺血药物。
Semin Thromb Hemost. 1996;22 Suppl 1:9-14.
8
Beneficial effects of defibrotide against myocardial ischemia and decline of beta-adrenoceptor function in the rabbit.
Haemostasis. 1986;16 Suppl 1:13-7. doi: 10.1159/000215334.
9
Defibrotide reduces monocyte PAI-2 and procoagulant activity.去纤苷降低单核细胞PAI-2和促凝血活性。
Semin Thromb Hemost. 1995;21(2):245-50. doi: 10.1055/s-2007-1000400.
10
The fibrinolytic mechanism of defibrotide: effect of defibrotide on plasmin activity.去纤苷的纤溶机制:去纤苷对纤溶酶活性的影响。
Blood Coagul Fibrinolysis. 2009 Dec;20(8):627-34. doi: 10.1097/MBC.0b013e32832da1e3.

引用本文的文献

1
Trends and Commonalities of Approved and Late Clinical-Phase RNA Therapeutics.获批及临床后期RNA疗法的趋势与共性
Pharmaceutics. 2025 Jul 12;17(7):903. doi: 10.3390/pharmaceutics17070903.
2
Immunosuppressive Treatment in Antiphospholipid Syndrome: Is It Worth It?抗磷脂综合征的免疫抑制治疗:是否值得?
Biomedicines. 2021 Feb 1;9(2):132. doi: 10.3390/biomedicines9020132.
3
Thrombotic microangiopathy in haematopoietic cell transplantation: an update.造血细胞移植中的血栓性微血管病:最新进展。
Mediterr J Hematol Infect Dis. 2010;2(3):e2010033. doi: 10.4084/MJHID.2010.033. Epub 2010 Nov 3.
4
Translational research efforts in biomarkers and biology of early transplant-related complications.转化研究在早期移植相关并发症的生物标志物和生物学方面的努力。
Biol Blood Marrow Transplant. 2011 Jan;17(1 Suppl):S101-8. doi: 10.1016/j.bbmt.2010.11.025.
5
Effective DNA inhibitors of cathepsin g by in vitro selection.通过体外筛选获得的组织蛋白酶G的有效DNA抑制剂
Int J Mol Sci. 2008 Jun;9(6):1008-1023. doi: 10.3390/ijms9061008. Epub 2008 Jun 20.
6
Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias.支持去纤苷治疗多发性骨髓瘤和其他肿瘤的临床前研究。
Clin Cancer Res. 2009 Feb 15;15(4):1210-21. doi: 10.1158/1078-0432.CCR-08-1270.